Melasma
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
O se tulaga masani e matauina i tamaitai Asia i le amataga o le 40s. Ole li'o li'o ile ata e latalata ile lentigo nai lo le melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Talu ai nei, low-fluence Q-switched Nd:YAG (LFQSNY) laser ua lauiloa mo le togafitia o le melasma, aemaise lava i Asia. O le otootoina o suʻesuʻega eseese sa luʻitau, ae o le LFQSNY e foliga mai e masani ona aoga ma saogalemu mo le melasma pe a faʻatusatusa i togafitiga masani. Ae ui i lea, o nisi tulaga o mottled hypopigmentation ua lipotia mai o se itu aʻafiaga o le LFQSNY, masalo ona o le maualuga o le malosi o le laser. O le fa'aaogaina malosi o le LFQSNY e mafai fo'i ona ta'ita'i atu i le hyperpigmentation mai le fula, aemaise ile pa'u o le pa'u.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
O faʻafitauli o le pigmentation e masani ona maua ile tausiga muamua. O ituaiga masani o fa'afitauli o le hyperpigmentation e aofia ai le post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Melasma e le mafai ona foia i le laser togafitiga mo se vaitaimi patino, ona o se faʻamaʻi lea e faʻaauau pea ona gaosia le pigmenti. O le Tranxenemic acid e fesoasoani e faʻaleleia atili ai le faʻaitiitia o le pigmentation.
○ Togafitiga
I nisi o atunuu (eg Iapani, Korea), o le oral tranexamic acid e maua i luga o le fata ma e aoga. Ole kulimi melasma ile tranexamic acid ma le azelaic acid e mafai ona fesoasoani tele.
O le hydroquinone e mafai ona fa'aoga fa'apitoa mo togafitiga o le hyperpigmentation, ae na taofia e le FDA oloa OTC o lo'o i ai le hydroquinone i le 2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma